Premium
Comparison of Nanoparticulate CpG Immunotherapy with and without Allergens in Rao‐Affected Horses
Author(s) -
Klier J.,
Geis S.,
Steuer J.,
Reese S.,
Fuchs S.,
Mueller R.S.,
Winter G.,
Gehlen H.
Publication year - 2015
Publication title -
equine veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.82
H-Index - 87
eISSN - 2042-3306
pISSN - 0425-1644
DOI - 10.1111/evj.12486_58
Subject(s) - medicine , immunotherapy , immunology , immune system , cpg oligodeoxynucleotide , allergy , cpg site , therapeutic effect , pharmacology , biology , biochemistry , gene expression , gene , dna methylation
Reasons for performing study N ew therapeutic strategies to modulate immune responses in human and equine allergic airway diseases are under extensive investigation. Stimulation of Treg cells with immune modulating agents is a novel therapeutic option. Objectives The aim of this field study was to compare the effects of a nebulised nanoparticulate CpG immunotherapy ( CpG ‐ GNP ) with and without specific allergens. Study design Longitudinal clinical study comparing 2 therapeutic options. Methods Twenty RAO ‐affected horses were divided into 2 treatment groups ( CpG alone and CpG with allergens). Two specific allergens were selected for each horse according to anamnesis and a functional in vitro test. Treatments were given by nebulisation 7 times and the horses were examined 3 times: baseline (I), after the treatment course (II), and after 6 weeks later (III). Clinical parameters, indirect intrapleural measurement, arterial blood gas, amount of tracheal mucus and neutrophil percentage were evaluated. Results CpG alone resulted in a significant improvement in clinical parameters and a significant reduction of tracheal mucus after treatment and at 6 weeks post treatment. After CpG plus specific allergens, there was significant improvement of 70% of examined parameters. However, there were no significant differences in the results compared with CpG ‐ GNP treatment alone. Conclusions There were no significant differences between treatment groups. CpG ‐ GNP immunotherapy alone produced a potent and persistent effect on allergic and inflammatory parameters and may have potential as for treatment of equine and human allergic inflammatory airway diseases. Ethical animal research: The study was approved by the regional legal agency for animal experiments of the Government of Bavaria, G ermany ( N o. 55.2‐1‐54‐2531‐31‐10). Owners gave informed consent for their horses' inclusion in the study. Sources of funding: Partly supported by the Deutsche Forschungsgemeinschaft ( DFG ) ( G ermany) ( GE '2044/4‐1). The AeroNeb Go™ vibrating mesh nebuliser ( A erogen, Galway, I reland) was sponsored by Inspiration Medical (Bochum, G ermany). Competing interests: None declared.